Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055978 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00055978 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 112 participants.
The verdict
NCT00055978, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing the development or recurrence of lung cancer in former heavy smokers. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing the development or recurrence of lung cancer in former heavy smokers who are at risk of developing cancer.
Interventions
- OTHER placebo
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2002-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055978
The ClinicalTrials.gov registry entry for NCT00055978 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00055978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055978 about?
NCT00055978 is a clinical study titled "Celecoxib in Preventing Lung Cancer in Former Heavy Smokers". RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing the development or recurrence of lung cancer in former heavy smokers. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib ...
What is the current status of trial NCT00055978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2002-10. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00055978?
The interventions under investigation include: placebo (OTHER), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00055978?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.